Novopharm says ranitidine ANDA purity standard is identical to Glaxo patent application.
This article was originally published in The Tan Sheet
Executive Summary
NOVOPHARM SAYS RANITIDINE FORM 1 PURITY STANDARD IN ANDA IS SAME AS GLAXO's standard used in patenting Form 2 Zantac. During arguments in patent litigation against Glaxo Wellcome in Elizabeth City, N.C., Novopharm attorneys claimed that Glaxo had flip-flopped on the purity standards for ranitidine since the two companies' last patent trial in 1993.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning